{"id":"loteprednol-etabonate-0-5-oph-gel","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or discomfort"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Ocular hypertension (elevated intraocular pressure)"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1200865","moleculeType":"Small molecule","molecularWeight":"466.96"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Loteprednol etabonate is a soft corticosteroid designed to minimize systemic absorption while providing potent local anti-inflammatory effects in ocular tissues. It reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene production, and suppressing immune cell infiltration. The ester structure allows rapid metabolism to inactive metabolites, reducing the risk of steroid-induced ocular hypertension and other systemic side effects.","oneSentence":"Loteprednol etabonate is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:09.071Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammation and pain following ocular surgery"},{"name":"Seasonal allergic conjunctivitis"},{"name":"Uveitis"},{"name":"Dry eye disease"}]},"trialDetails":[{"nctId":"NCT03123614","phase":"PHASE4","title":"Loteprednol vs. Prednisolone and Fluorometholone","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-19","conditions":"Intraocular Pressure, Corneal Opacity","enrollment":131},{"nctId":"NCT01437982","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-08-05","conditions":"Conjunctivitis, Seasonal Allergic, Conjunctivitis, Giant Papillary, Inflammation","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Loteprednol Etabonate 0.5% Oph Gel","genericName":"Loteprednol Etabonate 0.5% Oph Gel","companyName":"University of Utah","companyId":"university-of-utah","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Loteprednol etabonate is a topical corticosteroid that suppresses inflammatory responses in the eye by binding to glucocorticoid receptors and inhibiting inflammatory mediator production. Used for Inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, Post-operative inflammation following ocular surgery, Seasonal allergic conjunctivitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}